<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 25 percent of NHL cases [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The diagnostic category of DLBCL is heterogeneous in terms of morphology, genetics, and biologic behavior. A number of clinicopathologic entities are now recognized in the 2017 World Health Organization (WHO) classification that are sufficiently distinct to be considered separate diagnostic categories:</p><p class="bulletIndent1"><span class="glyph">●</span>T cell/histiocyte-rich large B cell lymphoma. (See <a class="local">'T cell histiocyte-rich large B cell lymphoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary DLBCL of the mediastinum, also called primary mediastinal (thymic) large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphomatoid granulomatosis, an Epstein-Barr virus positive large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">"Pulmonary lymphomatoid granulomatosis"</a> and <a class="local">'Lymphomatoid granulomatosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary DLBCL of the central nervous system. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary cutaneous DLBCL, leg type. (See  <a class="medical medical_review" href="/z/d/html/4715.html" rel="external">"Primary cutaneous large B cell lymphoma, leg type"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DLBCL associated with chronic inflammation. (See <a class="local">'Diffuse large B cell lymphoma associated with chronic inflammation'</a> below.)</p><p></p><p>Each of these is discussed separately in the sections that follow the general discussion of DLBCL or in their own topics. In addition, the WHO classification includes several disease categories that have features that overlap with DLBCL and other entities [<a href="#rid2">2,3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>"High grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements" and "high grade B cell lymphoma, not otherwise specified." Some tumors in this group were previously classified as "Burkitt-like" lymphoma. (See <a class="local">'Burkitt lymphoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma," sometimes referred to colloquially as "gray zone lymphoma." (See <a class="local">'Hodgkin lymphoma'</a> below.)</p><p></p><p>The epidemiology, clinical presentation, pathologic features, and diagnosis of DLBCL are reviewed in this topic.</p><p>The pathobiology and treatment of DLBCL and approach to the diagnosis, staging, and prognosis of the lymphomas are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas"</a> and  <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>DLBCL is the most common lymphoma and accounts for approximately 25 percent of all NHLs in the developed world [<a href="#rid1">1,4,5</a>]. In the United States and England, the incidence of DLBCL is approximately 7 cases per 100,000 persons per year [<a href="#rid1">1,6</a>]. In Europe as a whole, the incidence is approximately 4.92 cases per 100,000 persons per year [<a href="#rid7">7</a>]. Incidence varies by ethnicity, with White Americans having higher rates than Black, Asian, and American Indian or Alaska Native individuals, in order of decreasing incidence [<a href="#rid1">1,6,8</a>]. By comparison, the incidence in Denmark is approximately 3 cases per 100,000 adults per year [<a href="#rid9">9</a>]. DLBCL appears to be a more frequent subtype of NHL in Central and South America, where it accounts for approximately 40 percent of NHLs [<a href="#rid10">10</a>].</p><p>Like most other NHLs, there is a male predominance with approximately 55 percent of cases occurring in men [<a href="#rid1">1</a>]. Incidence increases with age; the median age at presentation is 64 years for patients as a whole, but appears to be younger for Black compared with White Americans [<a href="#rid11">11</a>]. Familial aggregation of patients with DLBCL and other NHL subtypes has been noted [<a href="#rid12">12,13</a>]. As an example, a large population-based observational study of patients from Sweden and Denmark reported that relatives of probands with aggressive NHL had an approximately 3.5-fold increased risk of developing NHL [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>DLBCL arises from a mature B cell and is usually comprised of cells resembling centroblasts or immunoblasts, two distinct types of activated B cells. The molecular pathogenesis of DLBCL is complex and includes both genetic lesions that are relatively specific for this disease (ie, rearrangements of <em>BCL6</em>) and molecular alterations that are shared with other NHL variants. The pathogenesis of DLBCL is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma"</a>.)</p><p>In addition to occurring de novo, DLBCL can arise through the transformation of many different types of low grade B cell lymphomas, including B cell chronic lymphocytic leukemia (eg, Richter's transformation), lymphoplasmacytic lymphoma, follicular lymphoma, marginal zone (MALT) lymphoma, and splenic marginal zone lymphoma. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p>DLBCL is an AIDS-defining malignancy. The pathogenesis of NHL in the setting of HIV infection is incompletely understood, but chronic B cell stimulation and T cell immunodeficiency leading to loss of control of transforming viruses, particularly Epstein-Barr virus (EBV), are thought to play important roles. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">"HIV-related lymphomas: Epidemiology, risk factors, and pathobiology"</a> and  <a class="medical medical_review" href="/z/d/html/4750.html" rel="external">"HIV-related lymphomas: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients with DLBCL typically present with a rapidly enlarging symptomatic mass, most usually nodal enlargement in the neck or abdomen, or, in the case of primary mediastinal large B cell lymphoma, the mediastinum, but may present as a mass lesion anywhere in the body. Extranodal involvement is common among those presenting with stage I/II disease [<a href="#rid14">14</a>]. Systemic "B" symptoms (ie, fever, weight loss, drenching night sweats) are observed in approximately 30 percent of patients, and the serum lactate dehydrogenase (LDH) is elevated in over one-half [<a href="#rid15">15,16</a>]. A more detailed discussion of systemic symptoms seen in patients with NHL is presented separately, along with the specific definitions of B symptoms. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Systemic "B" symptoms'</a>.)</p><p>Approximately 60 percent of patients will present with advanced stage DLBCL (usually stage III or IV disease) while 40 percent have more localized disease, usually defined as that which can be contained within one irradiation field  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 1</a>) [<a href="#rid15">15,16</a>]. The bone marrow is involved in up to 30 percent of cases, but may be of a discordant histologic type, such as follicular lymphoma [<a href="#rid17">17</a>], in as many as half of those cases. The staging of DLBCL is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Staging'</a>.)</p><p>In up to 40 percent of cases, the disease arises in extranodal extramedullary tissues [<a href="#rid9">9</a>]. The most common site of primary extranodal disease is the stomach/gastrointestinal tract  (<a class="graphic graphic_picture graphicRef51705" href="/z/d/graphic/51705.html" rel="external">picture 1</a>), but the disease can arise in virtually any tissue, including the testis, bone, thyroid, salivary glands, tonsil, skin, liver, breast, adrenals, kidneys, nasal cavity, ocular adnexa, paranasal sinuses, uterine cervix, vagina, and central nervous system [<a href="#rid18">18-41</a>]. Many of these presentations are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin (see  <a class="medical medical_review" href="/z/d/html/4715.html" rel="external">"Primary cutaneous large B cell lymphoma, leg type"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung (see <a class="local">'Lymphomatoid granulomatosis'</a> below and  <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">"Pulmonary lymphomatoid granulomatosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal tract (see  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinum (see  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (see  <a class="medical medical_review" href="/z/d/html/4693.html" rel="external">"Primary central nervous system lymphoma: Clinical features, diagnosis, and extent of disease evaluation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testis (see  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Testicular lymphoma'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart (see  <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">"Cardiac tumors"</a>)</p><p></p><p>Conversely, primary nodal disease may secondarily involve the liver, kidneys, lung, bone marrow, and central nervous system. DLBCL also can be locally highly invasive, leading to compression of vessels (eg, superior vena cava syndrome) or airways (eg, tracheo-bronchial compression), involvement of peripheral nerves, and destruction of bone (eg, cord compression), requiring urgent attention. (See  <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression"</a>.)</p><p>DLBCL is an AIDS-defining malignancy. When compared with lymphoma in the HIV-negative population, systemic lymphoma in the HIV-positive population is characterized by more frequent B symptoms (ie, fever, weight loss, night sweats), extranodal disease, involvement of unusual locations (eg, body cavity, rectum, soft tissue), and advanced stage at diagnosis. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4750.html" rel="external">"HIV-related lymphomas: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high (&gt;40 percent) proliferation fraction  (<a class="graphic graphic_picture graphicRef81533" href="/z/d/graphic/81533.html" rel="external">picture 2</a>).</p><p class="headingAnchor" id="H6"><span class="h2">Morphology</span></p><p class="headingAnchor" id="H1386915"><span class="h3">Typical morphology</span><span class="headingEndMark"> — </span>Lymph nodes usually demonstrate complete effacement of the normal architecture by sheets of atypical lymphoid cells. The tumor cells are of large size (eg, nuclei at least twice the size of a small lymphocyte and larger than the nucleus of a tissue macrophage) and often resemble normal centroblasts or immunoblasts  (<a class="graphic graphic_picture graphicRef67243" href="/z/d/graphic/67243.html" rel="external">picture 3</a>). Centroblasts are large, noncleaved cells with round or oval nuclei, vesicular chromatin, often multiple peripheral nucleoli, and a narrow rim of basophilic cytoplasm  (<a class="graphic graphic_picture graphicRef82926" href="/z/d/graphic/82926.html" rel="external">picture 4</a>). Immunoblasts are larger cells with very prominent nucleoli and abundant cytoplasm, often with plasmacytoid features  (<a class="graphic graphic_picture graphicRef82925" href="/z/d/graphic/82925.html" rel="external">picture 5</a>). Some tumors contain mixtures of centroblastic and immunoblastic forms.</p><p>In addition to the common centroblastic and immunoblastic morphologies, several other cytologic variants are recognized (eg, multilobated and anaplastic), but their clinical significance is debated [<a href="#rid42">42</a>]. In addition, there is poor intra- and inter-observer reproducibility among hematopathologists attempting to subtype DLBCL based on the appearance of the tumor cells, and as a result the morphologic subtypes of DLBCL are lumped together in a single diagnostic category in the current World Health Organization (WHO) classification of lymphoid neoplasms [<a href="#rid3">3</a>]. In contrast, plasmablastic lymphoma is a morphologic variant that displays immunophenotypic characteristics that allow for its distinction from other DLBCLs.</p><p class="headingAnchor" id="H1386908"><span class="h3">Plasmablastic lymphoma</span><span class="headingEndMark"> — </span>The tumor cells of plasmablastic lymphoma typically have large, eccentrically placed nuclei, often with prominent single nucleoli, and abundant basophilic cytoplasm, which together constitute a "plasmablast-like" appearance. Unlike the other morphologic variants described above, plasmablastic tumors are immunophenotypically distinct. Specifically, these tumors are comprised of late B cells that express plasma cell markers (eg, CD138) instead of the pan-B cell markers found in typical DLBCL (eg, CD20 and CD79a). Some tumors belonging to this group have distinctive genetic or clinicopathologic features. For example, oropharyngeal plasmablastic lymphomas occur most frequently in HIV-positive individuals and are often positive for Epstein-Barr virus. Another rare genetic subtype of plasmablastic lymphoma has rearrangements of the ALK tyrosine kinase gene, discussed in more detail below. Because of the plasmacellular differentiation of these tumors, they can be easily mistaken for anaplastic myeloma when they involve the bone marrow. (See  <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">"HIV-related lymphomas: Epidemiology, risk factors, and pathobiology"</a> and <a class="local">'Other mutations'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>The immunophenotype of DLBCL can be confirmed by histochemistry or flow cytometry  (<a class="graphic graphic_figure graphicRef77348" href="/z/d/graphic/77348.html" rel="external">figure 1</a>). Tumor cells in DLBCL generally express pan B cell antigens (CD19, CD20, CD22, CD79a), as well as CD45  (<a class="graphic graphic_picture graphicRef74703" href="/z/d/graphic/74703.html" rel="external">picture 6</a>). Fifty to 75 percent of tumors express surface or cytoplasmic monoclonal immunoglobulin (Ig), most often of the IgM isotype. The immunoglobulin variable region genes have undergone rearrangement and are commonly somatically mutated; clonally related subpopulations may express alternative isotypes (isotype switch variants) [<a href="#rid43">43</a>]. Expression of CD30 is present in approximately 25 percent of cases (particularly the anaplastic variant) and is associated with more favorable disease [<a href="#rid44">44,45</a>]. Uncommonly, DLBCLs express CD5, a finding associated with more aggressive disease and worse prognosis [<a href="#rid45">45-49</a>].</p><p>BCL2 protein is expressed in 25 to 80 percent of DLBCL  (<a class="graphic graphic_picture graphicRef65528" href="/z/d/graphic/65528.html" rel="external">picture 7</a>) [<a href="#rid50">50-55</a>]. Approximately 70 percent express B cell lymphoma 6 (BCL6) protein; this expression is independent of <em>BCL6</em> gene rearrangement  (<a class="graphic graphic_picture graphicRef53759" href="/z/d/graphic/53759.html" rel="external">picture 8</a>) [<a href="#rid53">53,54</a>]. Other markers that are commonly expressed include CD10 (30 to 60 percent of cases) and MUM1/IRF4 (35 to 65 percent of cases). Although MUM1/IRF4 and BCL6 are not coexpressed in normal B cells, coexpression of both markers is found in up to 50 percent of DLBCLs. The proliferative fraction of cells, as determined by Ki-67 staining, is usually higher than 40 percent, and may occasionally be &gt;90 percent, which may make distinguishing DLBCL from Burkitt lymphoma difficult in some cases  (<a class="graphic graphic_picture graphicRef77463" href="/z/d/graphic/77463.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Aberrant BCL6 expression'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Genetic features</span><span class="headingEndMark"> — </span>Most cases of DLBCL have genetic abnormalities, but there is no typical or diagnostic cytogenetic change. Most tumors demonstrate rearrangement of the immunoglobulin heavy and light chain genes and somatic mutations of the variable regions of these genes [<a href="#rid56">56,57</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Alterations in BCL6</span><span class="headingEndMark"> — </span>The <em>BCL6</em> gene, located on chromosome 3, is rearranged in 20 to 40 percent of cases and shows mutations in the 5' noncoding region in 70 percent [<a href="#rid58">58-62</a>]. Over 20 different translocations involving <em>BCL6</em> have been identified. Both 5' noncoding mutations of the <em>BCL6 </em>proto-oncogene and mutations of the immunoglobulin gene variable regions are found in normal germinal center cells [<a href="#rid63">63-65</a>]; their presence in DLBCL is consistent with a germinal center or post-germinal center stage of differentiation. The 5' noncoding mutations abolish negative autoregulation of expression by <em>BCL6</em>, which is a transcriptional repressor, whereas the translocations replace the <em>BCL6</em> promoter with strong, constitutively active promoters derived from many different genes. The net effect of both the mutations and translocations is the same: overexpression of BCL6, which is a common oncogenic mechanism in DLBCL. (See  <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Aberrant BCL6 expression'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">(14;18) translocation</span><span class="headingEndMark"> — </span>The t(14;18) seen in &gt;90 percent of cases of follicular lymphomas is also present in approximately 30 percent of patients with DLBCL. Such cases may represent histologic transformation of a prior follicular lymphoma or may be a de novo DLBCL subset demonstrating a germinal center B cell gene expression profile [<a href="#rid66">66,67</a>]. In cases of histologic transformation, mutations of <em>TP53</em> are observed at a high frequency as well as homozygous deletions at 9p21, which involve the p15 and p16 tumor suppressors [<a href="#rid68">68-71</a>]. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Histologic transformation'</a> and  <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'TP53 mutations'</a>.)</p><p>The t(14;18) is associated with nodal and disseminated disease, but is not associated with a worse prognosis. Furthermore, as with <em>BCL6</em>, expression of BCL2 is observed in many tumors without <em>BCL2</em> translocations [<a href="#rid50">50,72</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Other mutations</span><span class="headingEndMark"> — </span>Other abnormalities have been reported in DLBCL [<a href="#rid73">73-75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A comprehensive analysis of 363 cases of DLBCL found clonal karyotypic abnormalities in 87 percent [<a href="#rid73">73,74</a>]. The most common sites involved were 14q32, 18q21, 1q21, 3q27, 1q36, 8q24, 3p21, 6q21, 1p22, and 22q11. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <em>MYC</em> gene (ie, 8q24) is rearranged in 5 to 15 percent [<a href="#rid59">59,76-78</a>]. (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'MYC, BCL2, BCL6 abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rare plasmablastic forms of DLBCL have a (2;17)(p23;q23) translocation involving <em>ALK</em> and the clathrin gene (CLTC) [<a href="#rid79">79,80</a>]. These are late B cell tumors that are usually negative for CD20, CD79a, and CD30, positive for plasma cell markers such as CD138, and show granular cytoplasmic staining for ALK. Some series indicate a male predominance and a poor prognosis [<a href="#rid81">81,82</a>]. (See <a class="local">'Plasmablastic lymphoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deep sequencing of DLBCL genomes has identified over 400 different loci involved by tumor-specific somatic point mutations or recurrent copy number alterations [<a href="#rid83">83-85</a>], with most tumors harboring &gt;100 mutations in coding sequences (exons) alone. Of note, a number of the most frequently mutated genes encode enzymes that modify histones, including the histone acetyltransferases P300 and CREBP and the histone-lysine N-methyltransferase KMT2D (MLL2), suggesting that epigenetic changes in DLBCL cells are likely to have a central pathogenic role in these tumors.</p><p></p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H8316507"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The diagnosis of DLBCL is best made based by excisional tissue biopsy, most commonly a lymph node. While an excisional lymph node biopsy is the preferred diagnostic test for most patients, some patients do not present with overt lymphadenopathy and require the pathologic evaluation of another tissue (ie, pleural fluid, spleen) for diagnosis. A discussion of lymph node and tissue biopsy including the selection of a lymph node to biopsy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Lymph node and tissue biopsy'</a>.)</p><p class="headingAnchor" id="H8316514"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The pathologic diagnosis of DLBCL is based on morphology and immunophenotyping, which is essential to make the diagnosis. Staining for pan-B cell markers, such as CD20 and CD79a, is sufficient to establish the diagnosis in many cases, but a much broader set of stains may be needed in cases with atypical morphologic features. In rare cases with plasmablastic features, correlation with other clinical and laboratory features may be necessary to distinguish the tumor from multiple myeloma.</p><p>As described in more detail above, DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation fraction. Tumor cells in DLBCL generally express pan B cell antigens (CD19, CD20, CD22, CD79a). The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. </p><p class="headingAnchor" id="H886760911"><span class="h2">Molecular subtype</span><span class="headingEndMark"> — </span>The initial pathologic evaluation of DLBCL should include an assessment of molecular risk to further classify cases into germinal center B cell DLBCL and nongerminal center B cell lymphoma (including activated B cell lymphoma) and to identify double hit DLBCL [<a href="#rid2">2</a>]. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Molecular genetics'</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Clinical and laboratory'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of DLBCL includes other entities that can result in lymphadenopathy and similar pathologic features. These include infectious mononucleosis and malignancies such as carcinoma, melanoma, and other types of lymphoma  (<a class="graphic graphic_table graphicRef56467" href="/z/d/graphic/56467.html" rel="external">table 2</a>). These are described in more detail below.</p><p>The differential diagnosis of patients presenting with primary extranodal involvement depends upon the presenting symptoms. Many of these extranodal presentations are described in more detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin (see  <a class="medical medical_review" href="/z/d/html/4715.html" rel="external">"Primary cutaneous large B cell lymphoma, leg type"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung (see  <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">"Pulmonary lymphomatoid granulomatosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal tract (see  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinum (see  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (see  <a class="medical medical_review" href="/z/d/html/4693.html" rel="external">"Primary central nervous system lymphoma: Clinical features, diagnosis, and extent of disease evaluation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testis (see  <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Testicular lymphoma'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular lymphoma (see  <a class="medical medical_review" href="/z/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>)</p><p></p><p class="headingAnchor" id="H1202993"><span class="h2">Infectious mononucleosis</span><span class="headingEndMark"> — </span>Both infectious mononucleosis and the immunoblastic variant of DLBCL have prominent immunoblasts and Hodgkin-like cells on lymph node biopsy. However, T immunoblasts predominate in infectious mononucleosis, while large B cells predominate in DLBCL. (See  <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">"Infectious mononucleosis"</a>.)</p><p class="headingAnchor" id="H449901291"><span class="h2">"Gray zone lymphoma"</span><span class="headingEndMark"> — </span>The colloquial term "gray zone lymphoma" has been used by some to describe lymphomas with morphologic, immunophenotypic, and/or genotypic features that are either intermediate between DLBCL and Burkitt lymphoma (BL) or between DLBCL and Hodgkin lymphoma but do not clearly fit into any of these individual categories. These terms lack precision and are not used in the current World Health Organization (WHO) classification; as such, these entities should be categorized according to the descriptions below.</p><p class="headingAnchor" id="H3359365447"><span class="h3">Burkitt lymphoma</span><span class="headingEndMark"> — </span>The differentiation between DLBCL and Burkitt lymphoma (BL) can be difficult since DLBCL can have a high proliferation fraction and cytogenetic abnormalities, such as t(8;14), that are typically seen in BL, and BL can have atypical morphologic features, including some variation in cell size.</p><p>In the 2017 revision of the WHO classification system, a category previously described as "B cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL" was eliminated due to concerns regarding imprecision in the definition and inconsistency in its application [<a href="#rid2">2,3</a>]. Instead, the following was proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumors that show some atypical morphologic features but that have the immunophenotypic and genotypic features of BL should be categorized as BL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most tumors that have rearrangements of <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> (so-called "double hit" or "triple hit" lymphomas) have been placed in a new category, "high grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements," except for rare tumors that have these rearrangements but otherwise resemble lymphoblastic lymphoma or follicular lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cases that have morphologic features intermediate between DLBCL and BL and lack rearrangements in <em>MYC</em>, <em>BCL2</em>, and <em>BCL6</em> should be categorized as "high grade B cell lymphoma, not otherwise specified." </p><p></p><p>This remains a difficult and somewhat controversial diagnostic area and additional refinements are likely to be forthcoming.</p><p>Features that favor the diagnosis of DLBCL over BL or "high grade B cell lymphoma" include the presence of isolated cytogenetic abnormalities involving <em>BCL6</em> or <em>BCL2</em> and Ki-67 staining in less than 95 percent of the tumor cells. Expression of BCL2 (which is present in most DLBCLs and usually absent from BL) is helpful in distinguishing DLBCL from BL, but cannot distinguish between DLBCL and "high grade B cell lymphoma" with or without <em>MYC</em>, <em>BCL2</em>, and <em>BCL6</em> rearrangements, as these tumors frequently overexpress BCL2. Gene expression profiling also shows promise in distinguishing DLBCL from BL [<a href="#rid86">86,87</a>]. In contrast, "high grade B cell lymphoma" with or without <em>MYC</em>, <em>BCL2</em>, and <em>BCL6</em> rearrangements tend to have gene expression profiles intermediate between DLBCL and BL and are best recognized by other criteria (morphology, immunophenotype, and genotype). (See  <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Diffuse large B cell lymphoma'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Hodgkin lymphoma</span><span class="headingEndMark"> — </span>The 2017 WHO classification system provides an overlap category termed "B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma" [<a href="#rid2">2,3</a>]. This category includes tumors that morphologically resemble classical Hodgkin lymphoma, but have immunophenotypes that are more typical of DLBCL. </p><p>Some cases of the T cell histiocyte rich large B cell variant bear some resemblance to Hodgkin lymphoma of either the lymphocyte predominant or lymphocyte rich classic types [<a href="#rid88">88-91</a>]. Lymphocyte predominant Hodgkin lymphoma (LPHL) usually has a nodular growth pattern and presents with low-stage disease, in contrast to T cell/histiocyte-rich large B cell lymphoma, which grows in a diffuse pattern and typically presents with disseminated disease involving the liver and spleen. However, the distinction between unusual cases of advanced stage LPHL and T cell histiocyte rich large B cell lymphoma can be difficult, as the tumor cells in these two disorders have similar immunophenotypes. The lymphocyte rich subtype of classic Hodgkin lymphoma is usually more easily distinguished by expression of markers that are specific for classic forms of Hodgkin lymphoma, such as CD15 and CD30, and the presence of Epstein-Barr virus, which can be detected in 40 percent of lymphocyte rich classic Hodgkin lymphoma, but is not associated with T cell histiocyte rich large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a>.)</p><p>A potentially related issue is the occurrence of composite tumors containing areas of classic Hodgkin lymphoma and areas of DLBCL. Similarly, there may be sequential occurrence of both of these tumor types at different times in a patient's course; this situation arises most often in patients with primary mediastinal large B cell lymphoma, which shares certain genetic and immunophenotypic features with classical Hodgkin lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H17218451"><span class="h2">Anaplastic large cell lymphoma</span><span class="headingEndMark"> — </span>Cases of the anaplastic variant of DLBCL are morphologically identical to those of anaplastic large cell lymphoma (ALCL) T/null-cell type and strongly express CD30 (Ki-1). The key diagnostic criterion for such cases is the expression of B cell antigens, which are absent in ALCL. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p class="headingAnchor" id="H14074238"><span class="h2">Histologic transformation</span><span class="headingEndMark"> — </span>A subset of patients with pathologic findings consistent with DLBCL will have had a previously undiagnosed indolent lymphoma (eg, follicular lymphoma) that has undergone histologic transformation. Such patients may have a history of waxing and waning lymphadenopathy, with a more recent rapid progression of lymphadenopathy, infiltration of extranodal sites, development of systemic symptoms, and/or elevated serum lactate dehydrogenase (LDH).</p><p>Histology can vary greatly in different sections of the same lymph node. As such, careful examination of the sampled lymph node is key to determining whether a component of DLBCL is present. Discordant histologic features suggest transformation of a previously undiagnosed indolent lymphoma. As an example, a small B cell proliferation may be identified in the bone marrow in a patient with DLBCL in a lymph node. The detection of areas of DLBCL within the lymph node denotes transformation to an aggressive phase of disease. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H2471245754"><span class="h2">Carcinoma</span><span class="headingEndMark"> — </span>Morphologically, lymph node involvement with carcinoma may resemble DLBCL in that both tumors are comprised of large atypical cells. Carcinoma can be readily distinguished from DLBCL by the presence of cytokeratins and the absence of B cell markers by immunohistochemistry.</p><p class="headingAnchor" id="H905497734"><span class="h2">Melanoma</span><span class="headingEndMark"> — </span>Both melanoma and DLBCL are comprised of large atypical cells and can involve lymph nodes. However, unlike DLBCL, melanoma stains positively for S100, HMB-45, and/or Melan A and is negative for B cell markers. (See  <a class="medical medical_review" href="/z/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">DISTINCTIVE DLBCL SUBTYPES AND RELATED ENTITIES</span></p><p class="headingAnchor" id="H21"><span class="h2">T cell histiocyte-rich large B cell lymphoma</span><span class="headingEndMark"> — </span>All cases of DLBCL have some infiltrating reactive T cells and macrophages (histiocytes), but in some tumors these cells predominate. This is the so-called T cell histiocyte-rich large B cell lymphoma  (<a class="graphic graphic_picture graphicRef76125" href="/z/d/graphic/76125.html" rel="external">picture 10</a>). Some experts have suggested that less than 10 percent of the cellularity should be comprised of tumor cells for this diagnosis to be made.</p><p>In one study of 40 patients with this variant, the median age was 49 years (range: 21 to 87), with a male to female ratio of 2.6:1 [<a href="#rid92">92</a>]. Splenomegaly, bone marrow involvement, and hepatomegaly were present in 60, 43, and 40 percent, respectively. The International Prognostic Index (IPI)  (<a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">table 3</a>) was ≥2 in 77 percent of the patients. Neoplastic cells were uniformly positive for CD20 and negative for CD5, CD10, CD15, and CD138. Despite their relatively young age and the use of combination chemotherapy, complete remissions were attained in only 40 percent, with an overall survival of 50 percent at three years. On multivariate analysis, only the IPI and loss-of-function mutations (eg, deletions or point mutations) in p53 were predictive of failure-free survival. In another report, like primary mediastinal large B cell lymphoma, T cell histiocyte-rich large B cell lymphoma had amplification of <em>PDL1</em> gene in 64 percent of cases, a finding associated with high levels of PD-L1 expression [<a href="#rid93">93</a>].</p><p>In a separate study, there was no difference in five-year overall survival or event-free survival between this variant and DLBCL when subjects were matched for the prognostic features comprising the IPI [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Primary mediastinal large B cell lymphoma</span><span class="headingEndMark"> — </span>Primary large B cell lymphoma of the mediastinum is a distinct clinicopathologic entity that arises from the thymic (medullary) B cell. It has clinical and pathologic features that differ from DLBCL. (See  <a class="medical medical_review" href="/z/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Intravascular large B cell lymphoma</span><span class="headingEndMark"> — </span>Intravascular large B cell lymphoma, which is almost always of B-cell type (but occasionally of T cell origin [<a href="#rid95">95</a>] and rarely of NK-cell origin), usually presents with disseminated intravascular proliferation of large lymphoid cells involving small blood vessels without an obvious extravascular tumor mass or leukemia  (<a class="graphic graphic_picture graphicRef62103" href="/z/d/graphic/62103.html" rel="external">picture 11</a>). This tumor has been variously known as intravascular lymphomatosis, angiotropic large cell lymphoma, and malignant angioendotheliomatosis. The organs most commonly affected are the central nervous system, kidneys, lungs, and skin, but virtually any site may be involved. This disorder is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H740758010"><span class="h2">Diffuse large B cell lymphoma, leg type</span><span class="headingEndMark"> — </span>Diffuse large B cell lymphoma, leg type typically presents as red or bluish (violaceous) nodules or tumors on one or both legs, typically below the knee; 10 to 15 percent will develop outside of the lower extremities. Unlike other cutaneous B cell lymphomas, these tumors frequently disseminate to extracutaneous sites and pursue an aggressive course. DLBCL, leg type is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4715.html" rel="external">"Primary cutaneous large B cell lymphoma, leg type"</a>.)</p><p class="headingAnchor" id="H486128026"><span class="h2">Diffuse large B cell lymphoma associated with chronic inflammation</span><span class="headingEndMark"> — </span>DLBCL associated with chronic inflammation, which is also known as pyothorax-associated DLBCL, typically develops in patients with a lengthy (eg, several decades) history of pyothorax; similar tumors may arise at other sites of chronic inflammation [<a href="#rid96">96</a>]. These tumors are uniformly Epstein-Barr virus (EBV)-positive and are believed to arise from post-germinal center B cells that are latently infected with EBV. </p><p>The tumors often exhibit EBV latency III patterns of gene expression (LMP1 and EBNA2 are expressed), which has been taken to mean that the tumors arise in the context of local immunosuppression within the sites of chronic inflammation. DLBCL associated with chronic inflammation occurs worldwide, but it appears to be more common in Japan and China. In some large series, it is clinically aggressive, with five-year survival of 20 to 35 percent in the pre-rituximab era of CHOP (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) therapy [<a href="#rid96">96</a>]. </p><p class="headingAnchor" id="H763094"><span class="h2">Lymphomatoid granulomatosis</span><span class="headingEndMark"> — </span>Lymphomatoid granulomatosis is an EBV-positive large B cell lymphoma with a T cell-rich background that is clinically and pathologically distinct from DLBCL [<a href="#rid3">3,97</a>]. </p><p>Patients with lymphomatoid granulomatosis typically present with cough (60 percent), fever (60 percent), rash/nodules (40 percent), malaise (35 percent), weight loss (35 percent), neurological abnormalities (30 percent), dyspnea (30 percent), or chest pain (15 percent) [<a href="#rid98">98</a>]. Extranodal disease is common. Most patients have lung involvement at some point during their clinical course. Other commonly involved sites include the kidney, liver, brain, and skin. Lymph nodes and spleen are very rarely involved. Evidence of past or present immunodeficiency may be found.</p><p>Histologically, the infiltrates show extensive necrosis, often with only a few atypical large B cells in a pleomorphic background of lymphocytes, plasma cells, and histiocytes; the infiltrate may be both angiocentric and angioinvasive. The large atypical B cells are the neoplastic component and are latently infected with EBV. Pulmonary nodules may exhibit central necrosis and cavitation. (See  <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">"Pulmonary lymphomatoid granulomatosis"</a>.)</p><p>Although the infiltrates may resemble those of nasal/angiocentric lymphoma, there is no biological and little clinical overlap, since the latter is an NK cell or T cell neoplasm that involves the upper airway and midfacial region, skin, and sometimes the gastrointestinal tract, and rarely the lung or central nervous system. (See  <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type"</a>.)</p><p class="headingAnchor" id="H2612844"><span class="h2">EBV-positive DLBCL, NOS</span><span class="headingEndMark"> — </span>EBV-positive DLBCL, not otherwise specified (NOS), is a variant of DLBCL that replaced EBV-positive DLBCL of the elderly in the 2017 World Health Organization (WHO) classification, based on the recognition that it may occur in people of any age [<a href="#rid2">2,3</a>]. This is a clonal B cell lymphoproliferative disorder seen in patients without known immunodeficiency or prior lymphoma. It is differentiated from EBV-positive lymphomatoid granulomatosis (described above) based on morphology, as the EBV-positive neoplastic cells make up a major fraction of the tumor cellularity in EBV-positive DLBCL and are uncommon in EBV-positive lymphomatoid granulomatosis. </p><p>This entity is most common in Asian countries, where it accounts for 8 to 10 percent of DLBCL among patients without a known immunodeficiency [<a href="#rid99">99-102</a>]. Most patients present with extranodal disease, with or without nodal involvement. </p><p>While the initial reports were in adults &gt;50 years old, this entity has been increasingly recognized in younger patients [<a href="#rid100">100,103,104</a>]. One report described the occurrence of EBV-positive DLBCL in young patients (median age 23 years) without evidence of immunodeficiency [<a href="#rid103">103</a>]. EBV-positive tumor cells in these cases expressed the immune checkpoint marker PDL-1 and indoleamine 2,3-dioxygenase (IDO), an enzyme that participates in metabolic pathways implicated in induction of immune tolerance, both of which may contribute to "escape" of EBV-positive tumor cells from immune surveillance. (See <a class="local">'Lymphomatoid granulomatosis'</a> above.)</p><p class="headingAnchor" id="H3094814305"><span class="h2">EBV-positive mucocutaneous ulcer</span><span class="headingEndMark"> — </span>EBV-positive mucocutaneous ulcer is considered a provisional entity in the 2017 revision of the WHO classification [<a href="#rid2">2,3</a>]. It is defined by the presence of isolated, circumscribed, ulcerative lesions, typically occurring in elderly individuals, sometimes in the setting of immunosuppression [<a href="#rid105">105,106</a>]. The lesions are most common in the oropharynx but may also occur in the skin or in the gastrointestinal tract. The lesions contain a polymorphous inflammatory infiltrate mixed with scattered EBV-infected B cells, which frequently include cells resembling Hodgkin/Reed-Sternberg cells morphologically and immunophenotypically. The entity is distinguished from Hodgkin lymphoma by its extranodal presentation and retention of B cell markers on the tumor cells in most cases. Although the degree of cytologic atypia in the EBV-positive lesional cells is often striking, raising the possibility of EBV-positive DLBCL, this entity follows a benign course, with frequent spontaneous regressions and excellent responses to conservative treatment. </p><p class="headingAnchor" id="H1989821793"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/120191.html" rel="external">"Society guideline links: Management of diffuse large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H984778"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15855.html" rel="external">"Patient education: Diffuse large B cell lymphoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/691.html" rel="external">"Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse large B cell lymphoma (DLBCL)</strong> – DLBCL is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25 percent of NHL cases. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Patients usually present with an enlarging mass of lymph nodes in the neck or abdomen. One-third have systemic "B" symptoms (ie, fever, weight loss, sweats), while 30 percent have bone marrow involvement and 40 percent have extranodal disease. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphology</strong> – Lymph node architecture is typically effaced by sheets of large, atypical lymphocytes with prominent nucleoli and basophilic cytoplasm, diffuse growth pattern, and a high proliferation fraction  (<a class="graphic graphic_picture graphicRef81533" href="/z/d/graphic/81533.html" rel="external">picture 2</a>); the malignant cells resemble normal centroblasts  (<a class="graphic graphic_picture graphicRef82926" href="/z/d/graphic/82926.html" rel="external">picture 4</a>) or immunoblasts  (<a class="graphic graphic_picture graphicRef82925" href="/z/d/graphic/82925.html" rel="external">picture 5</a>). (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – Tumor cells generally express pan B cell antigens (CD19, CD20, CD22, CD79a)  (<a class="graphic graphic_picture graphicRef74703" href="/z/d/graphic/74703.html" rel="external">picture 6</a>). (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytogenetic/molecular</strong> – Most cases have cytogenetic (eg, t(14;18)) or molecular findings (eg, abnormal <em>BCL6</em>), but no single finding is typical or diagnostic. (See <a class="local">'Genetic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of DLBCL is based on characteristic morphology and immunophenotyping (described above) and is best determined with an excisional or incisional biopsy. If no nodal involvement is identified, the diagnosis can be made using extranodal tissue (eg, pleural fluid, spleen) (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Distinguishing between germinal center B cell DLBCL and nongerminal center B cell DLBCL (including activated B cell lymphoma) provides useful prognostic information. (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Molecular genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Other large cell malignancies, such as carcinoma, melanoma, and other types of lymphoma  (<a class="graphic graphic_table graphicRef56467" href="/z/d/graphic/56467.html" rel="external">table 2</a>), may present with a similar clinical presentation. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DLBCL subtypes</strong> – DLBCL is a heterogeneous category of NHL that includes distinct clinicopathologic entities, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T cell/histiocyte-rich large B cell lymphoma. (See <a class="local">'T cell histiocyte-rich large B cell lymphoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary mediastinal large B cell lymphoma. (See <a class="local">'Primary mediastinal large B cell lymphoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravascular large B cell lymphoma. (See <a class="local">'Intravascular large B cell lymphoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphomatoid granulomatosis, Epstein-Barr virus (EBV)-positive large B cell lymphoma. (See <a class="local">'Lymphomatoid granulomatosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>EBV-positive DLBCL, not otherwise specified (NOS). (See <a class="local">'EBV-positive DLBCL, NOS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary DLBCL of the central nervous system (CNS). (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary cutaneous DLBCL, leg type. (See  <a class="medical medical_review" href="/z/d/html/4715.html" rel="external">"Primary cutaneous large B cell lymphoma, leg type"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>DLBCL associated with chronic inflammation. (See <a class="local">'Diffuse large B cell lymphoma associated with chronic inflammation'</a> above.) </p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">van Leeuwen MT, Turner JJ, Joske DJ, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer 2014; 135:2146.</a></li><li><a class="nounderline abstract_t">Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.</a></li><li><a class="nounderline abstract_t">Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.</a></li><li><a class="nounderline abstract_t">Shirley MH, Sayeed S, Barnes I, et al. Incidence of haematological malignancies by ethnic group in England, 2001-7. Br J Haematol 2013; 163:465.</a></li><li><a class="nounderline abstract_t">Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. Br J Haematol 2004; 124:151.</a></li><li><a class="nounderline abstract_t">Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.</a></li><li><a class="nounderline abstract_t">Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2011; 117:2530.</a></li><li><a class="nounderline abstract_t">Goldin LR, Landgren O, McMaster ML, et al. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14:2402.</a></li><li><a class="nounderline abstract_t">Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.</a></li><li><a class="nounderline abstract_t">Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:1658.</a></li><li><a class="nounderline abstract_t">Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.</a></li><li><a class="nounderline abstract_t">A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.</a></li><li><a class="nounderline abstract_t">Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29:1452.</a></li><li><a class="nounderline abstract_t">Avilés A, Neri N, Huerta-Guzmán J. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients. J Surg Oncol 2002; 80:111.</a></li><li><a class="nounderline abstract_t">Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003; 21:2740.</a></li><li><a class="nounderline abstract_t">Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007; 136:521.</a></li><li><a class="nounderline abstract_t">Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2:109.</a></li><li><a class="nounderline abstract_t">Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol 2008; 65:183.</a></li><li><a class="nounderline abstract_t">Olivier KR, Brown PD, Stafford SL, et al. Efficacy and treatment-related toxicity of radiotherapy for early-stage primary non-Hodgkin lymphoma of the parotid gland. Int J Radiat Oncol Biol Phys 2004; 60:1510.</a></li><li><a class="nounderline abstract_t">Laskar S, Bahl G, Muckaden MA, et al. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer 2007; 110:816.</a></li><li><a class="nounderline abstract_t">Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19:3602.</a></li><li><a class="nounderline abstract_t">Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer 2001; 92:2023.</a></li><li><a class="nounderline abstract_t">Ribrag V, Bibeau F, El Weshi A, et al. Primary breast lymphoma: a report of 20 cases. Br J Haematol 2001; 115:253.</a></li><li><a class="nounderline abstract_t">Domchek SM, Hecht JL, Fleming MD, et al. Lymphomas of the breast: primary and secondary involvement. Cancer 2002; 94:6.</a></li><li><a class="nounderline abstract_t">Avilés A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69:256.</a></li><li><a class="nounderline abstract_t">Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma 2003; 4:154.</a></li><li><a class="nounderline abstract_t">Shikama N, Ikeda H, Nakamura S, et al. Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 2001; 51:1228.</a></li><li><a class="nounderline abstract_t">Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6.</a></li><li><a class="nounderline abstract_t">Oprea C, Cainap C, Azoulay R, et al. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol 2005; 131:468.</a></li><li><a class="nounderline abstract_t">Dursun P, Gultekin M, Bozdag G, et al. Primary cervical lymphoma: report of two cases and review of the literature. Gynecol Oncol 2005; 98:484.</a></li><li><a class="nounderline abstract_t">Monnard V, Sun A, Epelbaum R, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65:817.</a></li><li><a class="nounderline abstract_t">Kuo CC, Li WY, Huang CC, et al. Primary renal lymphoma. Br J Haematol 2009; 144:628.</a></li><li><a class="nounderline abstract_t">Lu NN, Li YX, Wang WH, et al. Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma. Cancer 2012; 118:1593.</a></li><li><a class="nounderline abstract_t">Guastafierro S, Tedeschi A, Criscuolo C, et al. Primary extranodal non-Hodgkin's lymphoma of the vagina: a case report and a review of the literature. Acta Haematol 2012; 128:33.</a></li><li><a class="nounderline abstract_t">de Leval L, Bonnet C, Copie-Bergman C, et al. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Ann Oncol 2012; 23:3143.</a></li><li><a class="nounderline abstract_t">Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol 2014; 89:310.</a></li><li><a class="nounderline abstract_t">Munch-Petersen HD, Rasmussen PK, Coupland SE, et al. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. JAMA Ophthalmol 2015; 133:165.</a></li><li><a class="nounderline abstract_t">De Paepe P, Achten R, Verhoef G, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23:7060.</a></li><li><a class="nounderline abstract_t">Ottensmeier CH, Stevenson FK. Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood 2000; 96:2550.</a></li><li><a class="nounderline abstract_t">Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol 2014; 167:608.</a></li><li><a class="nounderline abstract_t">Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121:2715.</a></li><li><a class="nounderline abstract_t">Stein H, Lennert K, Feller AC, Mason DY. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984; 42:67.</a></li><li><a class="nounderline abstract_t">Doggett RS, Wood GS, Horning S, et al. The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 1984; 115:245.</a></li><li><a class="nounderline abstract_t">Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood 2003; 101:699.</a></li><li><a class="nounderline abstract_t">Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99:815.</a></li><li><a class="nounderline abstract_t">Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90:244.</a></li><li><a class="nounderline abstract_t">Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14:2131.</a></li><li><a class="nounderline abstract_t">Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16:1931.</a></li><li><a class="nounderline abstract_t">Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30:803.</a></li><li><a class="nounderline abstract_t">de Leval L, Ferry JA, Falini B, et al. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol 2001; 25:1277.</a></li><li><a class="nounderline abstract_t">Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101:78.</a></li><li><a class="nounderline abstract_t">Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998; 162:261.</a></li><li><a class="nounderline abstract_t">Küppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol 1997; 27:1398.</a></li><li><a class="nounderline abstract_t">Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83:2423.</a></li><li><a class="nounderline abstract_t">Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92:3152.</a></li><li><a class="nounderline abstract_t">Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117:322.</a></li><li><a class="nounderline abstract_t">Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A 1995; 92:12520.</a></li><li><a class="nounderline abstract_t">Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol 1998; 9:55.</a></li><li><a class="nounderline abstract_t">Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood 1999; 93:2167.</a></li><li><a class="nounderline abstract_t">Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280:1750.</a></li><li><a class="nounderline abstract_t">Küppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 1993; 12:4955.</a></li><li><a class="nounderline abstract_t">Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99:2285.</a></li><li><a class="nounderline abstract_t">Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003; 9:2133.</a></li><li><a class="nounderline abstract_t">Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106:1770.</a></li><li><a class="nounderline abstract_t">Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.</a></li><li><a class="nounderline abstract_t">Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91:4677.</a></li><li><a class="nounderline abstract_t">Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88:3937.</a></li><li><a class="nounderline abstract_t">Papakonstantinou G, Verbeke C, Hastka J, et al. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113:383.</a></li><li><a class="nounderline abstract_t">Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92:234.</a></li><li><a class="nounderline abstract_t">Cigudosa JC, Parsa NZ, Louie DC, et al. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 1999; 25:123.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43:830.</a></li><li><a class="nounderline abstract_t">Yunis JJ, Mayer MG, Arnesen MA, et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320:1047.</a></li><li><a class="nounderline abstract_t">Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273.</a></li><li><a class="nounderline abstract_t">Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 2018; 131:2060.</a></li><li><a class="nounderline abstract_t">Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003; 102:2568.</a></li><li><a class="nounderline abstract_t">De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003; 102:2638.</a></li><li><a class="nounderline abstract_t">Morris SW. ALK in NHL: To B (cell) or not to B (cell)? Characterization of the entity "ALK+ DLBCL" (editorial). Blood 2003; 102:2316.</a></li><li><a class="nounderline abstract_t">Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27:4211.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189.</a></li><li><a class="nounderline abstract_t">Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.</a></li><li><a class="nounderline abstract_t">Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109:3879.</a></li><li><a class="nounderline abstract_t">Ennishi D, Jiang A, Boyle M, et al. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 2019; 37:190.</a></li><li><a class="nounderline abstract_t">Sha C, Barrans S, Cucco F, et al. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol 2019; 37:202.</a></li><li><a class="nounderline abstract_t">Delabie J, Vandenberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992; 16:37.</a></li><li><a class="nounderline abstract_t">McBride JA, Rodriguez J, Luthra R, et al. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol 1996; 20:193.</a></li><li><a class="nounderline abstract_t">Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102:3753.</a></li><li><a class="nounderline abstract_t">Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist 2006; 11:384.</a></li><li><a class="nounderline abstract_t">Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002; 20:1269.</a></li><li><a class="nounderline abstract_t">Griffin GK, Weirather JL, Roemer MGM, et al. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 2021; 137:1353.</a></li><li><a class="nounderline abstract_t">Bouabdallah R, Mounier N, Guettier C, et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 2003; 21:1271.</a></li><li><a class="nounderline abstract_t">Williams G, Foyle A, White D, et al. Intravascular T-cell lymphoma with bowel involvement: case report and literature review. Am J Hematol 2005; 78:207.</a></li><li><a class="nounderline abstract_t">Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002; 20:4255.</a></li><li><a class="nounderline abstract_t">Colby TV. Current histological diagnosis of lymphomatoid granulomatosis. Mod Pathol 2012; 25 Suppl 1:S39.</a></li><li><a class="nounderline abstract_t">Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979; 43:360.</a></li><li><a class="nounderline abstract_t">Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011; 16:87.</a></li><li><a class="nounderline abstract_t">Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011; 117:4726.</a></li><li><a class="nounderline abstract_t">Adam P, Bonzheim I, Fend F, Quintanilla-Martínez L. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 2011; 18:349.</a></li><li><a class="nounderline abstract_t">Hong JY, Yoon DH, Suh C, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol 2015; 26:548.</a></li><li><a class="nounderline abstract_t">Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 2015; 126:863.</a></li><li><a class="nounderline abstract_t">Said J. The expanding spectrum of EBV+ lymphomas. Blood 2015; 126:827.</a></li><li><a class="nounderline abstract_t">Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34:405.</a></li><li><a class="nounderline abstract_t">Hart M, Thakral B, Yohe S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol 2014; 38:1522.</a></li></ol></div><div id="topicVersionRevision">Topic 4703 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150940" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24639369" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045184" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664057" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033296" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence of haematological malignancies by ethnic group in England, 2001-7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687024" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23086753" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048801" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214923" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438470" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Highly increased familial risks for specific lymphoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20795790" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704731" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166827" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383296" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173380" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860953" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17156403" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11707851" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962036" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary testicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15590182" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and treatment-related toxicity of radiotherapy for early-stage primary non-Hodgkin lymphoma of the parotid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582622" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504742" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11596015" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Primary hepatic lymphoma: favorable outcome after combination chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11703318" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Primary breast lymphoma: a report of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815954" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lymphomas of the breast: primary and secondary involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166814" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Primary breast lymphoma: results of a controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715097" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Primary adrenal lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728681" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576916" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16281936" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992915" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary cervical lymphoma: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542791" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006569" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary renal lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21837667" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22584110" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Primary extranodal non-Hodgkin's lymphoma of the vagina: a case report and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22700993" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24273125" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25393033" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129841" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001910" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135752" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23343832" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6395656" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Immunohistological analysis of human lymphoma: correlation of histological and immunological categories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6232854" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393524" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11806981" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207459" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8683246" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586912" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10414499" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688462" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393466" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602370" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Somatic hypermutation in normal and transformed human B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209491" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8167331" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787151" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11972514" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618933" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541684" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090923" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nonimmunoglobulin gene hypermutation in germinal center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624052" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8262038" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895757" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796378" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886317" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400281" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : p53 mutations are associated with histologic transformation of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9616165" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916960" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380403" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639522" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chromosomal and gene amplification in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10337996" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804550" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Analysis of the coding genome of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2648153" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597184" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29475959" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763927" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750159" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : ALK in NHL: To B (cell) or not to B (cell)? Characterization of the entity "ALK+ DLBCL" (editorial)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636007" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21390126" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Inactivating mutations of acetyltransferase genes in B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796119" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343534" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30523716" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30523719" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728195" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554109" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881319" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16614234" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870169" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32871584" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663714" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726592" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Intravascular T-cell lymphoma with bowel involvement: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377970" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pyothorax-associated lymphoma: a review of 106 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22214969" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Current histological diagnosis of lymphomatoid granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/761171" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21212426" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385849" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21841405" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25475080" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999451" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272044" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The expanding spectrum of EBV+ lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154586" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25007145" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
